Neoadjuvant immunotherapy with chitosan and interleukin-12 to control breast cancer metastasis

OncoImmunology

Volumn 3, Issue 12, 2014, Pages 1-10

  Vo, Jimmy L N ^a   Yang, Lirong ^a   Kurtz, Samantha L ^a   Smith, Sean G ^a   Koppolu, Bhanu prasanth ^a   Ravindranathan, Sruthi ^a   Zaharoff, David A ^a  

^a University of Arkansas   (United States)

Author keywords

chitosan; cytokine delivery; interleukin 12; metastatic breast cancer; neoadjuvant immunotherapy

Indexed keywords

ALANINE AMINOTRANSFERASE; CHITOSAN; GAMMA INTERFERON; GLUCOSE; INTERLEUKIN 12;

4T1 TUMOR CELL; ADENOCARCINOMA; ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD CHEMISTRY; BREAST CANCER; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HYPOALBUMINEMIA; IMMUNOTHERAPY; INTESTINE PERFORATION; KIDNEY CARCINOMA; LEUKOPENIA; METASTASIS; MOUSE; NEUTROPENIA; NONHUMAN; PLEURA EFFUSION; PNEUMONIA; TOXICOLOGY; TUMOR CELL; TUMOR IMMUNITY;

EID: 84938812163     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/21624011.2014.968001     Document Type: Article

References (55)

1. R.Siegel, J.Ma, Z.Zou, A.Jemal. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29; PMID:24399786; http://dx.doi.org/10.3322/caac.21208
2. NCDB Analytic Cases: Disease site by American Joint Committee on Cancer Stage. NCDB Benchmark Reports; September 13, 2013. Available from: https://cromwell.facs.org/BMarks/BMCmp/ver10/Docs/. Accessed June 1, 2014
3. (EBCTCG) EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-717; PMID:15894097; http://dx.doi.org/10.1016/S0140-6736(05)66544-0
4. A.M.Brewster, G.N.Hortobagyi, K.R.Broglio, S.W.Kau, C.A.Santa-Maria, B.Arun, A.U.Buzdar, D.J.Booser, V.Valero, M.Bondy Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 2008; 100:1179-83; PMID:18695137; http://dx.doi.org/10.1093/jnci/djn233
5. C.Dong, L.Chen. Second malignancies after breast cancer: The impact of adjuvant therapy. Mol Clin Oncol 2014; 2:331-6; PMID:24772296
6. M.G.Hanna. Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer. Hum Vaccin Immunother 2012; 8:1156-60; PMID:22854664; http://dx.doi.org/10.4161/hv.20740
7. C.A.Klebanoff, N.Acquavella, Z.Yu, N.P.Restifo. Therapeutic cancer vaccines: are we there yet? Immunol Rev 2011; 239:27-44; PMID:21198663; http://dx.doi.org/10.1111/j.1600-065X.2010.00979.x
8. W.Lu, J.Su, L.S.Kim, C.D.Bucana, C.Donawho, J.He, I.J.Fidler, Z.Dong. Active specific immunotherapy against occult brain metastasis. Cancer Res 2003; 63:1345-50; PMID:12649197
9. M.Horinaga, K.M.Harsch, R.Fukuyama, W.Heston, W.Larchian. Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model. Urology 2005; 66:461-6; PMID:16040105; http://dx.doi.org/10.1016/j.urology.2005.03.052
10. M.P.Colombo, G.Trinchieri. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13:155-68; PMID:11900991; http://dx.doi.org/10.1016/S1359-6101(01)00032-6
11. K.Boggio, G.Nicoletti, E.Di Carlo, F.Cavallo, L.Landuzzi, C.Melani, M.Giovarelli, I.Rossi, P.Nanni, C.De Giovanni Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2neu transgenic mice. J Exp Med 1998; 188:589-96; PMID:9687535; http://dx.doi.org/10.1084/jem.188.3.589
12. W.Y.Pan, C.H.Lo, C.C.Chen, P.Y.Wu, S.R.Roffler, S.K.Shyue, M.H.Tao. Cancer immunotherapy using a membrane-bound interleukin-12 with B7-1 transmembrane and cytoplasmic domains. Mol Ther 2012; 20:927-37; PMID:22334018; http://dx.doi.org/10.1038/mt.2012.10
13. A.L.Rakhmilevich, K.Janssen, Z.Hao, P.M.Sondel, N.S.Yang. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism. Cancer Gene Ther 2000; 7:826-38; PMID:10880012; http://dx.doi.org/10.1038/sj.cgt.7700176
14. J.P.Leonard, M.L.Sherman, G.L.Fisher, L.J.Buchanan, G.Larsen, M.B.Atkins, J.A.Sosman, J.P.Dutcher, N.J.Vogelzang, J.L.Ryan. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997; 90:2541-8; PMID:9326219
15. M.A.Cheever. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008; 222:357-68; PMID:18364014; http://dx.doi.org/10.1111/j.1600-065X.2008.00604.x
16. D.Chinnasamy, Z.Yu, S.P.Kerkar, L.Zhang, R.A.Morgan, N.P.Restifo, S.A.Rosenberg. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res 2012; 18:1672-83; PMID:22291136; http://dx.doi.org/10.1158/1078-0432.CCR-11-3050
17. M.R.Simpson-Abelson, V.S.Purohit, W.M.Pang, V.Iyer, K.Odunsi, T.L.Demmy, S.J.Yokota, J.L.Loyall, R.J.KelleherJr, S.Balu-Iyer IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments. Clin Immunol 2009; 132:71-82; PMID:19395317; http://dx.doi.org/10.1016/j.clim.2009.03.516
18. M.L.Salem, W.E.Gillanders, A.N.Kadima, S.El-Naggar, M.P.Rubinstein, M.Demcheva, J.N.Vournakis, D.J.Cole. Review: novel nonviral delivery approaches for interleukin-12 protein and gene systems: curbing toxicity and enhancing adjuvant activity. J Interferon Cytokine Res 2006; 26:593-608; PMID:16978064; http://dx.doi.org/10.1089/jir.2006.26.593
19. B.Sangro, I.Melero, C.Qian, J.Prieto. Gene therapy of cancer based on interleukin 12. Curr Gene Ther 2005; 5:573-81; PMID:16457647; http://dx.doi.org/10.2174/156652305774964712
20. M.Cemazar, T.Jarm, G.Sersa. Cancer electrogene therapy with interleukin-12. Curr Gene Ther 2010; 10:300-11; PMID:20560875; http://dx.doi.org/10.2174/156652310791823425
21. S.Hallaj-Nezhadi, F.Lotfipour, C.Dass. Nanoparticle-mediated interleukin-12 cancer gene therapy. J Pharm Pharm Sci: Pub Can Soc Pharm Sci, Soc Can Des Sci Pharm 2010; 13:472-85; PMID:21092717
22. K.Anwer, M.N.Barnes, J.Fewell, D.H.Lewis, R.D.Alvarez. Phase-I clinical trial of IL-12 plasmidlipopolymer complexes for the treatment of recurrent ovarian cancer. Gene therapy 2010; 17:360-9; PMID:20033066; http://dx.doi.org/10.1038/gt.2009.159
23. A.I.Daud, R.C.DeConti, S.Andrews, P.Urbas, A.I.Riker, V.K.Sondak, P.N.Munster, D.M.Sullivan, K.E.Ugen, J.L.Messina Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol: Off J Am Soc Clin Oncol 2008; 26:5896-903; PMID:19029422; http://dx.doi.org/10.1200/JCO.2007.13.9048
24. N.K.Egilmez, Y.S.Jong, M.S.Sabel, J.S.Jacob, E.Mathiowitz, R.B.Bankert. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res 2000; 60:3832-7; PMID:10919657
25. N.K.Egilmez, M.O.Kilinc, T.Gu, T.F.Conway. Controlled-release particulate cytokine adjuvants for cancer therapy. Endocr Metab Immune Disord Drug Targets 2007; 7:266-70; PMID:18220947; http://dx.doi.org/10.2174/187153007782794335
26. D.A.Zaharoff, K.W.Hance, C.J.Rogers, J.Schlom, J.W.Greiner. Intratumoral immunotherapy of established solid tumors with chitosanIL-12. J Immunother 2010; 33:697-705; PMID:20664357; http://dx.doi.org/10.1097/CJI.0b013e3181eb826d
27. D.A.Zaharoff, B.S.Hoffman, H.B.Hooper, C.J.Benjamin, K.K.Khurana, K.W.Hance, C.J.Rogers, P.A.Pinto, J.Schlom, J.W.Greiner. Intravesical immunotherapy of superficial bladder cancer with chitosaninterleukin-12. Cancer Res 2009; 69:6192-9; PMID:19638573; http://dx.doi.org/10.1158/0008-5472.CAN-09-1114
28. K.Pogoda, A.Niwińska, M.Murawska, T.Pieńkowski. Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol 2013; 30:388; PMID:23292831; http://dx.doi.org/10.1007/s12032-012-0388-4
29. C.J.Aslakson, F.R.Miller. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992; 52:1399-405; PMID:1540948
30. B.A.Pulaski, S.Ostrand-Rosenberg. Mouse 4T1 breast tumor model. Curr Protoc Immunol 2001; 39:20.2:20.2.1–20.2.16; PMID:18432775; http://dx.doi.org/10.1002/0471142735.im2002s39
31. C.Guiducci, E.Di Carlo, M.Parenza, M.Hitt, M.Giovarelli, P.Musiani, M.P.Colombo. Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor. J Immunol 2004; 172:4026-36; PMID:15034014; http://dx.doi.org/10.4049/jimmunol.172.7.4026
32. M.Gil, M.Seshadri, M.P.Komorowski, S.I.Abrams, D.Kozbor. Targeting CXCL12CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proc Natl Acad Sci U S A 2013; 110:E1291-300; PMID:23509246; http://dx.doi.org/10.1073/pnas.1220580110
33. M.S.Sabel, G.Su, K.A.Griffith, A.E.Chang. Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer. Breast Cancer Res Treat 2010; 122:325-36; PMID:19802695; http://dx.doi.org/10.1007/s10549-009-0570-3
34. M.S.Sabel, H.Hill, Y.S.Jong, E.Mathiowitz, R.B.Bankert, N.K.Egilmez. Neoadjuvant therapy with interleukin-12-loaded polylactic acid microspheres reduces local recurrence and distant metastases. Surgery 2001; 130:470-8; PMID:11562672; http://dx.doi.org/10.1067/msy.2001.115839
35. M.O.Kilinc, K.S.Aulakh, R.E.Nair, S.A.Jones, P.Alard, M.M.Kosiewicz, N.K.Egilmez. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effectormemory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors. J Immunol 2006; 177:6962-73; PMID:17082611; http://dx.doi.org/10.4049/jimmunol.177.10.6962
36. M.O.Kilinc, T.Gu, J.L.Harden, L.P.Virtuoso, N.K.Egilmez. Central role of tumor-associated CD8+ T effectormemory cells in restoring systemic antitumor immunity. J Immunol 2009; 182:4217-25; PMID:19299720; http://dx.doi.org/10.4049/jimmunol.0802793
37. M.O.Kilinc, R.B.Rowswell-Turner, T.Gu, L.P.Virtuoso, N.K.Egilmez. Activated CD8 +T-effectormemory cells eliminate CD4+ CD25+ Foxp3+ T-suppressor cells from tumors via FasL mediated apoptosis. J Immunol 2009; 183:7656-60; PMID:19923444; http://dx.doi.org/10.4049/jimmunol.0902625
38. T.Gu, M.O.Kilinc, N.K.Egilmez. Transient activation of tumor-associated T-effectormemory cells promotes tumor eradication via NK-cell recruitment: minimal role for long-term T-cell immunity in cure of metastatic disease. Cancer Immunol, Immunother: CII 2008; 57:997-1005; PMID:18049819; http://dx.doi.org/10.1007/s00262-007-0430-0
39. S.K.Watkins, N.K.Egilmez, J.Suttles, R.D.Stout. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J Immunol 2007; 178:1357-62; PMID:17237382; http://dx.doi.org/10.4049/jimmunol.178.3.1357
40. A.Sharma, C.M.Harper, L.Hammer, R.E.Nair, E.Mathiowitz, N.K.Egilmez. Characterization of cytokine-encapsulated controlled-release microsphere adjuvants. Cancer Biother Radiopharm 2004; 19:764-9; PMID:15665625; http://dx.doi.org/10.1089/cbr.2004.19.764
41. M.Slota, J.B.Lim, Y.Dang, M.L.Disis. ELISpot for measuring human immune responses to vaccines. Expert Rev Vaccines 2011; 10:299-306; PMID:21434798; http://dx.doi.org/10.1586/erv.10.169
42. Y.Yamaguchi, A.Ohshita, Y.Kawabuchi, J.Hihara, E.Miyahara, K.Noma, T.Toge. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: treatment of Th1 dysfunction in the ascites microenvironment. Int J Oncol 2004; 24:959-66; PMID:15010836
43. M.L.Disis, K.Schiffman, T.A.Gooley, D.G.McNeel, K.Rinn, K.L.Knutson. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2neu peptide immunization. Clin Cancer Res 2000; 6:1347-50; PMID:10778962
44. S.E.Strome, S.Voss, R.Wilcox, T.L.Wakefield, K.Tamada, D.Flies, A.Chapoval, J.Lu, J.L.Kasperbauer, D.Padley Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res 2002; 62:1884-9; PMID:11912169
45. K.Takeda, N.Yamaguchi, H.Akiba, Y.Kojima, Y.Hayakawa, J.E.Tanner, T.J.Sayers, N.Seki, K.Okumura, H.Yagita Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 2004; 199:437-48; PMID:14769851; http://dx.doi.org/10.1084/jem.20031457
46. N.K.Egilmez, M.O.Kilinc. Tumor-resident CD8+ T-cell: the critical catalyst in IL-12-mediated reversal of tumor immune suppression. Arch Immunol Ther Exp (Warsz) 2010; 58:399-405; PMID:20872283; http://dx.doi.org/10.1007/s00005-010-0097-7
47. E.Bajetta, M.Del Vecchio, R.Mortarini, R.Nadeau, A.Rakhit, L.Rimassa, C.Fowst, A.Borri, A.Anichini, G.Parmiani. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res 1998; 4:75-85; PMID:9516955
48. J.A.Gollob, J.W.Mier, K.Veenstra, D.F.McDermott, D.Clancy, M.Clancy, M.B.Atkins. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 2000; 6:1678-92; PMID:10815886
49. M.C.Rodriguez-Galan, D.Reynolds, S.G.Correa, P.Iribarren, M.Watanabe, H.A.Young. Coexpression of IL-18 strongly attenuates IL-12-induced systemic toxicity through a rapid induction of IL-10 without affecting its antitumor capacity. J Immunol 2009; 183:740-8; PMID:19535628; http://dx.doi.org/10.4049/jimmunol.0804166
50. J.E.Portielje, C.H.Lamers, W.H.Kruit, A.Sparreboom, R.L.Bolhuis, G.Stoter, C.Huber, J.W.Gratama. Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses. Clin Cancer Res 2003; 9:76-83; PMID:12538454
51. G.Trinchieri. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3:133-46; PMID:12563297; http://dx.doi.org/10.1038/nri1001
52. R.L.Elliott, J.F.Head, J.L.McCoy. Comparison of estrogen and progesterone receptor status to lymphocyte immunity against tumor antigens in breast cancer patients. Breast Cancer Res Treat 1994; 30:299-304; PMID:7981448; http://dx.doi.org/10.1007/BF00665971
53. C.N.Baxevanis, I.F.Voutsas, A.D.Gritzapis, S.A.Perez, M.Papamichail. HER-2neu as a target for cancer vaccines. Immunotherapy 2010; 2:213-26; PMID:20635929; http://dx.doi.org/10.2217/imt.09.89
54. A.C.Wolff, M.E.Hammond, D.F.Hayes. Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCOCAP HER2-positivity criteria. J Natl Cancer Inst 2012; 104:957-8; PMID:22581974; http://dx.doi.org/10.1093/jnci/djs243
55. R.Dent, M.Trudeau, K.I.Pritchard, W.M.Hanna, H.K.Kahn, C.A.Sawka, L.A.Lickley, E.Rawlinson, P.Sun, S.A.Narod. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13:4429-34; PMID:17671126; http://dx.doi.org/10.1158/1078-0432.CCR-06-3045